Securities code: 688298 securities abbreviation: Zhejiang Orient Gene Biotech Co.Ltd(688298) Announcement No.: 2022-001 Zhejiang Orient Financial Holdings Group Co.Ltd(600120) gene biological products Co., Ltd
Announcement of annual performance increase in 2021
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
1、 Performance forecast of the current period
(I) performance forecast period
From January 1, 2021 to December 31, 2021.
(II) performance forecast
(1) According to the preliminary calculation of the financial department, the net profit attributable to the owners of the parent company is expected to reach 4.72 billion yuan to 5.12 billion yuan in 2021, an increase of 3.043 billion yuan to 3.443 billion yuan, a year-on-year increase of 181.45% to 205.31% compared with the same period of the previous year (legally disclosed data).
(2) The net profit attributable to the owners of the parent company after deducting non recurring profits and losses is RMB 4.7 billion to RMB 5.1 billion, which will increase by RMB 3.041 billion to RMB 3.441 billion compared with the same period of the previous year (legally disclosed data), with a year-on-year increase of 183.30% to 207.41%.
(III) this performance forecast has not been audited by certified public accountants.
2、 Performance in the same period of last year
Net profit attributable to owners of the parent company in the same period of last year: 1.677 billion yuan. Net profit attributable to the owner of the parent company after deducting non recurring profits and losses: 1.659 billion yuan.
3、 Main reasons for performance changes in the current period
1. Main business impact: 2021 continued to be affected by the global COVID-19 epidemic. New Coronavirus antigen rapid detection reagent (including family self testing) continued to be put into the epidemic prevention business, and its sales performance in the European market continued to grow significantly, prompting a significant increase in operating performance in 2021.
2. Other impacts: there are no major influencing factors such as non recurring profits and losses and accounting treatment.
4、 Risk tips
1. The company has no major uncertain factors affecting the accuracy of the performance forecast, and the performance forecast has not been audited by certified public accountants.
2. In 2021, the company’s operating performance mainly depends on covid-19 testing reagent. Whether the future performance can continue to maintain rapid growth is subject to major uncertainty, which mainly depends on the progress of global covid-19 epidemic prevention and control, the selection of covid-19 testing products by various countries, the company’s product market competitiveness and channel sales capacity, and the future development of conventional business, Please pay attention to investment risks.
5、 Other explanatory matters
The above forecast data are only preliminary accounting data. The specific and accurate financial data shall be subject to the audited annual report of 2021 officially disclosed by the company. Please pay attention to the investment risks.
It is hereby announced.
Board of directors of Zhejiang Orient Financial Holdings Group Co.Ltd(600120) gene biological products Co., Ltd
January 15, 2022
